Loading...

AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 580 GBX +0.02% Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one AZN stock under the Base Case scenario is 19 036.01 GBX. Compared to the current market price of 10 580 GBX, AstraZeneca PLC is Undervalued by 44%.

The Intrinsic Value is calculated as the average of the two valuation methods:

AZN Intrinsic Value
Base Case
19 036.01 GBX
Undervaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

AZN Profitability Score
Profitability Due Diligence

AstraZeneca PLC's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Positive 3-Year Average ROIC
Positive Net Income
Declining ROE
Positive ROE
59/100
Profitability
Score

AstraZeneca PLC's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

AZN Solvency Score
Solvency Due Diligence

AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Positive Net Debt
Short-Term Liabilities
Average Interest Coverage
Average Altman Z-Score
46/100
Solvency
Score

AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
79%
Gross Margin
17%
Operating Margin
5%
Net Margin
13%
FCF Margin
5%
ROE
15%
ROIC
Other

AZN Capital Structure
AstraZeneca PLC

Market Capitalization 164B GBX
Total Debt 24.3B GBX
Minority Interest 20M GBX
Preferred Equity 0 GBX
Cash and Equivalents 4.5B GBX
Short-Term Investments 440M GBX
Enterprise Value 183B GBX

Wall St
Price Targets

AZN Price Targets Summary
AstraZeneca PLC

Wall Street analysts forecast AZN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AZN is 12 262.42 GBX with a low forecast of 6 741.86 GBX and a high forecast of 18 375 GBX.

Lowest
Price Target
6 741.86 GBX
36% Downside
Average
Price Target
12 262.42 GBX
16% Upside
Highest
Price Target
18 375 GBX
74% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

AZN Competitors
AstraZeneca PLC

AZN Suppliers & Customers
AstraZeneca PLC

AstraZeneca PLC has 133 key suppliers from 14 countries and 16 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
64
Veeva Systems Inc
Health Care
Evercore Inc
Financial Services
Emergent BioSolutions Inc
Biotechnology
Thermo Fisher Scientific Inc
Life Sciences Tools & Services
D
DoubleVerify Holdings Inc
Technology
Darling Ingredients Inc
Food Products
ChargePoint Holdings Inc
Electrical Equipment
Model N Inc
Technology
Arcus Biosciences Inc
Biotechnology
Biohaven Pharmaceutical Holding Company Ltd
Biotechnology
Box Inc
Technology
Catalent Inc
Pharmaceuticals
Invitae Corp
Health Care
Merck & Co Inc
Pharmaceuticals
O
ON24 Inc
Technology
Eli Lilly and Co
Pharmaceuticals
Aptargroup Inc
Packaging
A
Akoya Biosciences Inc
Life Sciences Tools & Services
Honeywell International Inc
Industrial Conglomerates
F-Star Therapeutics Inc
Biotechnology
Insmed Inc
Biotechnology
Amgen Inc
Biotechnology
Inovio Pharmaceuticals Inc
Biotechnology
R
Royalty Pharma PLC
Pharmaceuticals
V
Viant Technology Inc
Technology
Vir Biotechnology Inc
Biotechnology
9
908 Devices Inc.
Electrical Equipment
D
Definitive Healthcare Corp
Health Care
Schrodinger Inc
Health Care
Halozyme Therapeutics Inc
Biotechnology
Veracyte Inc
Biotechnology
4
4D Molecular Therapeutics Inc
Biotechnology
Certara Inc
Health Care
Coupa Software Inc
Technology
Guardant Health Inc
Health Care
C
Cyteir Therapeutics Inc
Biotechnology
B
Biodesix Inc
Health Care
Aveo Pharmaceuticals Inc
Biotechnology
Rigel Pharmaceuticals Inc
Biotechnology
Moderna Inc
Biotechnology
Arcutis Biotherapeutics Inc
Biotechnology
FibroGen Inc
Biotechnology
Nektar Therapeutics
Pharmaceuticals
Bridgeline Digital Inc
Technology
Equinix Inc
Real Estate
NVIDIA Corp
Semiconductors
Ironwood Pharmaceuticals Inc
Biotechnology
DocuSign Inc
Technology
Ovid Therapeutics Inc
Biotechnology
A
Avalo Therapeutics Inc
Biotechnology
Myriad Genetics Inc
Biotechnology
Harvard Bioscience Inc
Life Sciences Tools & Services
Adaptive Biotechnologies Corp
Life Sciences Tools & Services
Ionis Pharmaceuticals Inc
Biotechnology
Hackett Group Inc
Technology
Clovis Oncology Inc
Biotechnology
Fortress Biotech Inc
Biotechnology
PhaseBio Pharmaceuticals Inc
Biotechnology
P
Pieris Pharmaceuticals Inc
Biotechnology
Regeneron Pharmaceuticals Inc
Biotechnology
Biocept Inc
Biotechnology
OPTIMIZERx Corp
Health Care
BridgeBio Pharma Inc
Biotechnology
S
Strategic Asset Leasing Inc
Financial Services
Suppliers Map

AstraZeneca PLC has 60 key customers from 11 countries and 8 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Customers Map

Shareholder Return

AZN Price
AstraZeneca PLC

1M 1M
-10%
6M 6M
-1%
1Y 1Y
+27%
3Y 3Y
+37%
5Y 5Y
+124%
Annual Price Range
10 580
52w Low
8 281.4763
52w High
11 802
Price Metrics
Average Annual Return 16.47%
Standard Deviation of Annual Returns 14.57%
Max Drawdown -13%
Shares Statistics
Market Capitalization 164B GBX
Shares Outstanding 1 549 529 984
Percentage of Shares Shorted
N/A

Company Profile

AstraZeneca PLC

Country

United Kingdom

Industry

Pharmaceuticals

Market Cap

164B GBP

Dividend Yield

2.16%

Description

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The firm is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The firm has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Contact

CAMBRIDGESHIRE
Cambridge
1 Francis Crick Avenue
+11442073045000.0
https://www.astrazeneca.com/Home

IPO

2007-09-21

Employees

83 100

Officers

CEO & Exec. Director
Mr. Pascal Soriot D.V.M., M.B.A.
CFO & Exec. Director
Dr. Aradhana Sarin M.D.
CEO of Alexion & Chief Strategy Officer
Mr. Marc Dunoyer
EVP of Operations & Information Technology and Member of External Sustainability Advisory Board
Ms. Pam P. Cheng
Head of Investor Relations
Mr. Chris Sheldon
Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board
Mr. Jeffrey Pott
Show More
EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board
Ms. Katarina Ageborg
Head of Global Media Relations
Gonzalo Vina
EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
Dr. Menelas Pangalos Ph.D.
Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
Dr. Ruud Dobber Ph.D.
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one AZN stock?

The intrinsic value of one AZN stock under the Base Case scenario is 19 036.01 GBX.

Is AZN stock undervalued or overvalued?

Compared to the current market price of 10 580 GBX, AstraZeneca PLC is Undervalued by 44%.